NV-RIMINI-STREET
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of business software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced the appointment of Michael L. Perica as executive vice president and chief financial officer (CFO) to support the Company’s next phase of growth. Perica leads the finance strategy and execution for Rimini Street and its global subsidiaries, and is responsible for all financial operations of the Company including global financial planning and analysis, accounting, revenue management, global treasury and tax, SEC reporting, finance systems and processes, audit, capital structure, capital markets activities, M&A and investor relations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005035/en/
Successful 25 Year Track-Record in Financial Management and Capital Markets
Perica brings extensive public technology company financial leadership and capital markets experience to his new role at Rimini Street. Most recently, Perica served as vice president of finance and CFO of the $1.4 billion Energy Systems Global business unit at Enersys (NYSE: ENS), a global leader in stored energy solutions, where he led finance, treasury, tax, legal and HR. Perica joined Enersys as the result of a $750 million acquisition, where he led the sell-side process as CFO of Alpha Technologies, a leading provider of power conversion equipment, services and software to the telecommunications, renewable and industrial sectors. Prior to the sale of Alpha Technologies to Enersys, as CFO of Alpha Technologies, Perica developed and executed a strategic financial plan that resulted in a five-year period of double-digit compounded annual revenue and EBITDA growth driven by services expansion and acquisitions. Prior to his tenure at Alpha Technologies, Perica served as CFO of Channell Commercial Corporation, a leading provider of outdoor enclosures and wire management solutions. Earlier, Perica spent 12 years at various Wall Street investment banks and concluded his capital markets career as senior vice president and head of research at Brean Capital (formerly Brean Murray, Carret & Co.). Earlier in his capital markets career, Perica led the technology, media and telecommunications practice at Kaufman Bros., led the technology practice at Gruntal & Co. and was a Zacks and Reuters top-rated analyst for communications equipment at Olde Financial Corp. where he advised client boards on IPOs, secondary offerings and other capital raise strategies and plans.
“Rimini Street is a well-run, disruptive and visionary leader in the fast-growing, global third-party enterprise software support market. The Company’s value proposition and business model has served the needs of more than 3,500 clients to date, including 175 Fortune 500 and Global 100 clients, and I believe is the optimal solution for tens of thousands of additional enterprises around the world,” said Perica. “I am excited about joining the Company at this stage of its growth and I am looking forward to partnering with CEO Seth Ravin and the rest of our incredibly talented and experienced senior executive team and Board to deliver accelerating growth, improving free cash flow and growing GAAP profitability.”
“Michael brings a wealth of experience to his new role as CFO of Rimini Street including a successful track record in financial planning, operations, capital markets, M&A and shareholder relations,” said Seth A. Ravin , Rimini Street co-founder, CEO and chairman of the board. “I look forward to partnering with Michael to grow our global business, provide more value to our clients and deliver better returns for our shareholders.”
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 3,500 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com , follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn . (IR-RMNI)
Forward-Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the duration of and economic, operational and financial impacts on Rimini Street’s business of the COVID-19 pandemic, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt Rimini Street’s business or that of its current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; Rimini Street’s need and ability to raise additional equity or debt financing on favorable terms and Rimini Street’s ability to generate cash flows from operations to help fund increased investment in Rimini Street’s growth initiatives; the sufficiency of Rimini Street’s cash and cash equivalents to meet its liquidity requirements; the terms and impact of Rimini Street’s outstanding 13.00% Series A Preferred Stock; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of Rimini Street’s recently introduced products and services, including its Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services Rimini Street expects to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those risks discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on August 5, 2020 and as updated from time to time by other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2020 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 13:00:00 CEST | Press release
FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letterIf approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 13:00:00 CEST | Press release
Experts from Qualcomm, Viant Medical, and Thermo Fisher Scientific join Kinaxis and economic futurist Andrew Busch to share insights on navigating tariff volatility As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s comin
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
Craig Cook appointed Chief Business Officer and Co-founder at ABILITY Neurotech, the Wyss Geneva’s flagship spin-off12.6.2025 09:00:00 CEST | Press release
The Wyss Center for Bio and Neuroengineering proudly announces the appointment of Craig Cook, former Head of Business Development & Licensing at the Center, as Chief Business Officer and Co-founder of ABILITY Neurotech SA, a pioneering spin-off company translating breakthrough brain-computer interface (BCI) technology into clinical impact. During his tenure at the Wyss Center, Craig Cook played a transformative role in establishing a strong business development framework and positioning the organization as a venture builder in neurotechnology. Under his leadership, six breakthrough technologies were successfully spun out into operational startup companies: Clee Medical SA, Brainscape Medical SA, Dataflight Ltd, BrainQuant SA, Aleos Bio SA, and ABILITY Neurotech SA. In parallel, Craig led the onboarding of aligned startups such as Dandelion Science Corp. and dEEGtal Insights SA, strengthening our AI and neurotech ecosystem. He also contributed to Series A investments in two Wyss-affilia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom